Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

This study is ongoing, but not recruiting participants.
Mayo Clinic
Information provided by (Responsible Party):
Bristol-Myers Squibb Identifier:
First received: October 19, 2010
Last updated: February 10, 2014
Last verified: February 2014

The purpose of this study is to evaluate oral doses of BMS-754807 in combination with letrozole or BMS-754807 alone are safe and efficacious in locally advanced or metastatic hormone receptor positive breast cancer subjects who have progressed with prior non-steroidal aromatase inhibitor treatment.

Condition Intervention Phase
Breast Cancer
Drug: BMS-754807
Drug: letrozole
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors

Resource links provided by NLM:

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Progression free survival rate at 24 weeks [ Time Frame: 24 weeks after initiating study treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Assess the objective response rate and duration of response in subjects with measurable disease [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Safety through adverse event reporting and laboratory abnormalities [ Time Frame: 24 weeks and ongoing during the study until discontinuation of study medication (through last patient last visit) ] [ Designated as safety issue: Yes ]
  • Treatment failure rate [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Anti-proliferative effects using FLT-PET ([18F]-3'-deoxy-3'-fluorothymidine positron emitting tomography) [ Time Frame: 14 days after initiating study treatment ] [ Designated as safety issue: No ]
  • Describe changes in various biomarkers related to breast cancer [ Time Frame: Ongoing during the study until discontinuation of study medication (about every 30 days until last patient last visit) ] [ Designated as safety issue: No ]

Estimated Enrollment: 100
Study Start Date: June 2011
Estimated Study Completion Date: September 2014
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BMS-754807 Drug: BMS-754807
Tablet, Oral, 100 mg, Daily, Until disease progression or unacceptable toxicity
Experimental: BMS-754807 + letrozole Drug: BMS-754807
Tablet, Oral, 100 mg, Daily, Until disease progression or unacceptable toxicity
Drug: letrozole
Tablets, Oral, 2.5 mg, Daily, Until disease progression or unacceptable toxicity
Other Name: Femara®


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

For more information regarding BMS clinical trial participation, please visit

Inclusion Criteria:

  • Postmenopausal women with hormone receptor-positive and HER-2 negative breast cancer
  • Disease progression following non-steroidal aromatase inhibitor treatment

Exclusion Criteria:

  • Known symptomatic brain metastasis
  • Medical condition requiring chronic steroids
  • History of Type 1 or 2 Diabetes
  • Uncontrolled or significant cardiovascular (CV) disease
  • Concomitant second malignancies
  Contacts and Locations
Please refer to this study by its identifier: NCT01225172

United States, Alabama
Univ Of Al At Birmingham
Birmingham, Alabama, United States, 35249
United States, Arizona
Donald W. Hill M.D., P.C.
Casa Grande, Arizona, United States, 85122
Mayo Clinic Arizona
Scottsdale, Arizona, United States, 85259
United States, California
Sharp Clinical Oncology Research
San Diego, California, United States, 92123
United States, Georgia
Georgia Cancer Specialists I, Pc
Atlanta, Georgia, United States, 30341
United States, Illinois
Illinois Cancercare, Pc
Peoria, Illinois, United States, 61615
United States, Maryland
The Sidney Kimmel Comprehensive Cancer Ctr At Johns Hopkins
Baltimore, Maryland, United States, 21231
Northwest Hospital Center
Randallstown, Maryland, United States, 21133
United States, Minnesota
Masonic Cancer Ctr, University Of Minnesota
Minneapolis, Minnesota, United States, 55455
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, North Carolina
Unv. Of Nc At Chapel Hill
Chapel Hill, North Carolina, United States, 27599
Presbyterian Hospital Cancer Research
Charlotte, North Carolina, United States, 28204
Duke University Medical Center-Dept Of Medicine
Durham, North Carolina, United States, 27710
United States, Rhode Island
Pharma Resource
East Providence, Rhode Island, United States, 02915
United States, Texas
The University Of Texas Md Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Bristol-Myers Squibb
Mayo Clinic
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
No publications provided

Responsible Party: Bristol-Myers Squibb Identifier: NCT01225172     History of Changes
Other Study ID Numbers: CA191-011
Study First Received: October 19, 2010
Last Updated: February 10, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Aromatase Inhibitors
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on April 14, 2014